SGLT2 inhibitors were originally developed as antidiabetic drugs, and accumulating evidence has supported the use of SGLT2 inhibitors for the treatment of patients with either heart failure or chronic kidney disease, regardless of the presence or absence of diabetes, mainly based on the EMPEROR-reduced trial [24], DAPA-HF trial [25], and DAPA-CKD trial [26]. Here, SLC5A2 is linked to heart failure.